KALV has been the subject of a number of other reports. Leerink Swann assumed coverage on shares of Kalvista Pharmaceuticals in a report on Monday, July 29th. They issued an outperform rating and a $31.00 price target for the company. Roth Capital reissued a buy rating on shares of Kalvista Pharmaceuticals in a report on Tuesday, May 28th. Svb Leerink assumed coverage on shares of Kalvista Pharmaceuticals in a report on Monday, July 29th. They issued an outperform rating and a $31.00 price target for the company. TheStreet downgraded shares of Kalvista Pharmaceuticals from a c- rating to a d+ rating in a report on Thursday, July 11th. Finally, Zacks Investment Research downgraded shares of Kalvista Pharmaceuticals from a buy rating to a sell rating in a report on Wednesday, July 17th. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and seven have given a buy rating to the company’s stock. The company presently has an average rating of Buy and a consensus price target of $29.86.
Kalvista Pharmaceuticals stock traded down $0.33 during mid-day trading on Tuesday, reaching $15.62. The company had a trading volume of 30,520 shares, compared to its average volume of 153,750. Kalvista Pharmaceuticals has a 52 week low of $12.14 and a 52 week high of $34.92. The stock’s 50 day simple moving average is $18.43. The stock has a market cap of $274.56 million, a price-to-earnings ratio of -11.32 and a beta of 2.10.
In other Kalvista Pharmaceuticals news, Director Albert Cha acquired 26,500 shares of Kalvista Pharmaceuticals stock in a transaction dated Friday, July 26th. The stock was bought at an average cost of $16.83 per share, with a total value of $445,995.00. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Edward P. Feener sold 3,300 shares of the firm’s stock in a transaction dated Tuesday, July 23rd. The stock was sold at an average price of $18.62, for a total transaction of $61,446.00. Following the transaction, the insider now directly owns 98,634 shares of the company’s stock, valued at $1,836,565.08. The disclosure for this sale can be found here. Insiders have bought a total of 145,427 shares of company stock valued at $2,515,550 over the last ninety days. 38.40% of the stock is owned by insiders.
Large investors have recently added to or reduced their stakes in the company. Strs Ohio bought a new position in shares of Kalvista Pharmaceuticals during the 2nd quarter worth about $68,000. Bank of Montreal Can lifted its holdings in shares of Kalvista Pharmaceuticals by 28.5% during the 1st quarter. Bank of Montreal Can now owns 5,824 shares of the specialty pharmaceutical company’s stock worth $166,000 after acquiring an additional 1,292 shares during the period. Marshall Wace North America L.P. bought a new position in shares of Kalvista Pharmaceuticals during the 1st quarter worth about $175,000. Swiss National Bank bought a new position in shares of Kalvista Pharmaceuticals during the 2nd quarter worth about $390,000. Finally, Wells Fargo & Company MN lifted its holdings in shares of Kalvista Pharmaceuticals by 3.2% during the 2nd quarter. Wells Fargo & Company MN now owns 35,710 shares of the specialty pharmaceutical company’s stock worth $791,000 after acquiring an additional 1,103 shares during the period. 80.01% of the stock is owned by institutional investors.
Kalvista Pharmaceuticals Company Profile
KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.
Featured Article: What is a recession?
Receive News & Ratings for Kalvista Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kalvista Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.